full access: DNA Methylation Profiles of Ovarian Epithelial Carcinoma Tumors and Cell Lines

Table 1

Histology and clinical characteristics of primary ovarian tumors. (serous, endometrioid, clear cell - CA125 levels, menopausal status,patient age)

Background

Epithelial ovarian carcinoma is a significant cause of cancer mortality in women worldwide and in the United States. Epithelial ovarian cancer comprises several histological subtypes, each with distinct clinical and molecular characteristics. The natural history of this heterogeneous disease, including the cell types of origin, is poorly understood.

full access: Feb 19, 2010 Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?

Note: study of 41 women

abstract: Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?

OBJECTIVE: "To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatology in patients with recurrent epithelial ovarian cancer (EOC) who have achieved a complete response following primary therapy..... 

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer

Conclusion: Intraperitoneal chemotherapy regimens using carboplatin or cisplatin and dropping day 8 IP paclitaxel have less toxicity and less discontinuation of therapy

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment

Ovarian Cancer Alliance of Nevada (OCAN) - Updates

abstract: From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer

Note: patients enrolled between January 2006 to December 2007 "Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered."

Grants.gov - 2010 (research) Ovarian Cancer

Expected Number of Awards: 12
Estimated Total Program Funding: $4,100,000

Description:

NEW for FY10, the OCRP Translational Pilot Award mechanism supports innovative translational research addressing a critical problem or question in ovarian cancer that will accelerate the movement of promising ideas toward clinical applications.

MicroRNAs in ovarian carcinomas -- Dahiya and Morin 17 (1): F77 -- Endocrine-Related Cancer

(abstract) FOCUS REVIEW
MicroRNAs in ovarian carcinomas
Neetu Dahiya1 and Patrice J Morin1,2
1 Laboratory of Cellular and Molecular Biology, National Institute on Aging, NIH Biomedical Research Center, 251 Bayview Boulevard, Suite 100, Room 6C228, Baltimore, Maryland 21224, USA
2 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA

In Research: Magnetic Nanoparticles Latch On, Ferry Cancer Cells Out of Body

includes reference to ovarian cancer

Searching for the roots of ovarian cancer | Health & Fitness News - OregonLive.com

"It's very frustrating for patients and for researchers that there hasn't been significant advances in ovarian cancer," says Dr. Tanja Pejovic, a gynecologic oncologist and associate professor at Oregon Health & Science University......Pejovic's group at OHSU is among those seeking to understand the basic biology as a means to zero in on likely markers of early disease. In a study reported in December, the group monitored the action of 69 genes in cells that make up the ovarian surface epithelium. They identified a set of genes that appear to become more active as cells progress from normal to cancerous......"We are still trying to understand early events," she says. But Pejovic remains optimistic."We have to understand early events to the point where it can lead us to markers that circulate in the blood."

Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.

The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer -- Helm 14 (7): 683 -- The Oncologist

Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes

Note: highly technical paper comparing serous, clear cell and endometrioid ovarian cancer cells type/endometriosis/Interleukins (in research)

Ovarian Cancer Trial RESULTS - National Cancer Institute

Ovarian Cancer Symptoms Speak Out--But What Are They Really Saying? -- Cass and Karlan, 10.1093/jnci/djp525 -- JNCI Journal of the National Cancer Institute

Ovarian Cancer Symptoms Speak Out--But What Are They Really Saying? -- Cass and Karlan, 10.1093/jnci/djp525 -- JNCI Journal of the National Cancer Institute

Pelvic symptoms unlikely to mean ovarian cancer | Reuters

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

"METHODS:: Patients with stage III/IV EOC received cyclophosphamide 750 mg/m(2), followed by a 24-hour infusion of paclitaxel 250 mg/m(2) and cisplatin 75 mg/m(2) on Day 2. Filgrastim began on Day 3 at 10 mug/kg daily for 9 days. Patients received 6 cycles of all drugs." CONCLUSIONS:: The studied regimen yielded a high response rate and encouraging overall survival."

abstract: Review The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer

BRCA1 185delAG mutant protein, BRAt, up-regulates Maspin in ovarian epithelial cells

"Consequently, understanding early genotypic and phenotypic changes in the context of high risk disease may provide a better understanding of the mechanism of mutation-associated ovarian cancer and provide new targets for therapeutic intervention."